Two States, Two Rsponses: How Tamil Nadu's Swift Ban Exposes Madhya Pradesh's Deadly Delay
Toxic cough syrup kills 9 kids in MP as TN acts within 24 hours.
A heartbreaking tragedy has unfolded in Madhya Pradesh, where nine young lives—Shivam, Vidhi, Adnan, Usaid, Rishika, Hetansh, Vikas, Chanchalesh, and Sandhya—have been cut short, with grieving families pointing fingers at two cough syrups, Coldrif and Nextros DS, prescribed for routine fever and cough treatments. The children, all under the age of 10, first sought care at local clinics for mild fevers, only to receive these over-the-counter remedies.
Within days, a cascade of horrifying symptoms emerged: relentless vomiting, severe diarrhea, and the chilling cessation of urination—hallmark indicators of acute kidney failure triggered by Diethylene Glycol (DEG) contamination. This industrial solvent, commonly used in paints and antifreeze rather than pharmaceuticals, mirrors the 2022 Gambia crisis that claimed over 70 children's lives due to similar adulterated syrups, raising urgent alarms about India's drug manufacturing oversight and supply chain vulnerabilities.
The sequence of events in Madhya Pradesh paints a picture of systemic inertia amid mounting evidence. Families report that the children were prescribed the syrups at a clinic in Parasia, a coal-mining town in Chhindwara district, where access to quality healthcare is already strained. Post-mortem renal biopsies, as quietly conceded by senior health officials like Dr. Prabhakar Tiwari of the National Health Mission, reveal kidneys ravaged by a toxic substance consistent with DEG poisoning—swollen tubules, necrotic tissues, and irreversible damage that no amount of dialysis could reverse.
Yet, state authorities have adopted a posture of cautious denial, with Health Minister Rajendra Shukla asserting that preliminary tests on samples "did not show any substance" linking the deaths to the medications. Sub-Divisional Magistrate Shubham Yadav echoed this, attributing the fatalities to "common causes" like contaminated water, rat-borne infections, or mosquito vectors, while admitting samples are still pending lab analysis. Sales of the implicated syrups have been halted preemptively, but no comprehensive recall or manufacturer probe has been announced, leaving families in a limbo of frustration and fear that more children could be at risk.
In stark contrast, Tamil Nadu's Drugs Control Department demonstrated a model of decisive governance when alerted to the crisis. On October 1—a public holiday—the state received an urgent letter from Madhya Pradesh flagging Coldrif Syrup batch SR-13, produced by Sresan Pharmaceuticals in Kanchipuram. Undeterred by the timing, a team of inspectors descended on the facility that evening, uncovering a litany of lapses: 39 critical violations in manufacturing protocols, including inadequate quality controls and unhygienic lab conditions, alongside 325 major infractions under the Drugs and Cosmetics Act. Samples from Coldrif and four other syrups were immediately seized, stocks frozen on-site, and rushed to the Chennai government laboratory for expedited DEG and ethylene glycol assays.
By October 2, the analyst's Form-13 report confirmed the nightmare: the batch was adulterated with 48.6% DEG, rendering it "not of standard quality" and a direct threat to renal health, while the other samples passed muster. This rapid turnaround, as hailed by Deputy Director S. Gurubharathi, marks a national first—completing inspection, testing, and enforcement in under 48 hours, even over a holiday weekend.
Also Read: Tamil YouTuber Felix Gerald Arrested for Spreading Misinformation on Karur Stampede
Tamil Nadu's response cascaded into protective measures that Madhya Pradesh has yet to emulate. A statewide alert was disseminated within hours, directing all drug inspectors to quarantine any remaining stocks at wholesalers, retailers, and pharmacies, with distribution records traced to neighboring Odisha and Puducherry for coordinated action. On October 3, a formal stop-production order was slapped on Sresan Pharmaceuticals in the public interest, accompanied by a show-cause notice threatening license revocation and a public advisory urging citizens to surrender suspect bottles.
This proactive shield not only safeguards Tamil Nadu's 7.5 crore residents but also sets a benchmark for interstate collaboration, underscoring how embedded lab networks and a vigilant regulatory framework can avert widespread harm. Gurubharathi emphasized that such alacrity stems from post-Gambia reforms, including mandatory DEG screening protocols, yet lamented that not all states have invested in similar infrastructure.
The disparities extend beyond Madhya Pradesh, with Rajasthan's handling drawing sharp criticism for victim-blaming amid three similar child deaths in its border districts. Health Minister Gajendra Singh Khimsar dismissed departmental accountability, claiming the syrups were "not prescribed by government doctors" but self-purchased by parents, and that tests cleared the drugs of fault. This deflection ignores the unregulated private clinics proliferating in rural India, where low-cost generics often bypass stringent checks.
As families in Madhya Pradesh bury their children—clutching faded prescription slips and demanding justice—the nation grapples with a poignant query: If Tamil Nadu can pivot from alert to ban in a day, why do other states prioritize bureaucratic foot-dragging over the imperative of child safety? With over 66,000 pharmacies in Madhya Pradesh alone and a history of 2023's substandard drug alerts, experts call for a centralized national task force to harmonize responses, lest more innocent lives dissolve into this toxic shadow.
Also Read: Vijay’s TVK Launches High-Octane Campaign in Namakkal, Karur
